It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Pfizer, Mochida Tie Up for Antidepressant Desvenlafaxine in Japan
April 2, 2019
- Takeda Files Adcetris for PTCL, Pediatric Use in Japan
April 1, 2019
- Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
April 1, 2019
- Safety Monitoring Board Backs PIII Continuation for Elenbecestat: Eisai
April 1, 2019
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Takeda Spin-Off Startup Chordia Raises 3 Billion Yen to Fund Oncology R&D
April 1, 2019
- Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
March 29, 2019
- Janssen Files Stelara for Ulcerative Colitis in Japan
March 29, 2019
- Ono Seeks Japan Approval for Opdivo in MSI-H Colorectal Cancer
March 29, 2019
- Pfizer Japan to Stop Hiring Smokers
March 29, 2019
- Astellas/Seattle Genetics’ ADC Succeeds in PII Urothelial Cancer Study; US Filing Set for 2nd Half of 2019
March 29, 2019
- After 70% Pricing OK’ed for Biosame, Nesp Biosimilar Developers Stay Pat on November Listing Plans
March 28, 2019
- Ono Hooks Up with UK Charities in Cancer Immunotherapy
March 28, 2019
- Daiichi Sankyo Kicks Off Asia PIII for Mirogabalin
March 28, 2019
- Chugai’s SMA Drug Risdiplam Gets Orphan Status
March 28, 2019
- JSR Enters Strategic Partnership with Dutch Institute in Oncology Field
March 28, 2019
- Astellas’ Vasomotor Symptom Treatment Fezolinetant Smashes Primary Goals in US PIIb Study
March 28, 2019
- Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- Fujifilm, NCC Join Hands for I/O Research, Combining Liposomes with Immune Checkpoint Inhibitors
March 27, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…